Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Board Change

26 Jan 2023 08:00

Arix Bioscience PLC (ARIX)


Board Change

26-Jan-2023 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Board Change

London, 26 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces Dr Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.

Peregrine Moncreiffe, Chairman of Arix, commented: “On behalf of the Board, I would like to thank Benny for the support he has shown to the Company since joining the Board last year and wish him well in his future endeavours.”

[ENDS]

 

For more information, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 



ISIN: GB00BD045071
Category Code: BOA
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 218423
EQS News ID: 1543761

 
End of Announcement EQS News Service


fncls.ssp?fn=show_t_gif&application_id=1543761&application_name=news&site_id=london_south_east
Date   Source Headline
16th Mar 20237:01 amEQSUnaudited NAV for February 2023
14th Feb 20236:19 pmEQSPortfolio company Disc Medicine announces $62.5 million financing
6th Feb 20236:00 pmEQSDirector/PDMR Shareholding
6th Feb 20235:00 pmEQSDirector/PDMR Shareholding
6th Feb 20238:00 amEQSUnaudited NAV for January 2023
6th Feb 20237:00 amEQSUnaudited NAV for January 2023
30th Jan 20238:00 amEQSUnaudited NAV for December 2022
30th Jan 20237:00 amEQSUnaudited NAV for December 2022
26th Jan 20238:00 amEQSBoard Change
26th Jan 20237:00 amEQSBoard Change
5th Jan 20235:20 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 20234:21 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 20228:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 20227:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 20228:00 amEQSUnaudited NAV for November 2022
12th Dec 20227:01 amEQSUnaudited NAV for November 2022
6th Dec 20228:00 amEQSArix to Present at Mello Investment Trusts & Funds
6th Dec 20227:00 amEQSArix to Present at Mello Investment Trusts & Funds
1st Dec 20227:45 amRNSDirector/PDMR Shareholding
9th Nov 20228:00 amEQSUnaudited NAV for October 2022
9th Nov 20227:00 amEQSUnaudited NAV for October 2022
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
20th Oct 20224:30 pmEQSHolding(s) in Company
20th Oct 20224:30 pmEQSHolding(s) in Company
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
3rd Oct 20224:32 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 20224:31 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 20227:01 amEQSUnaudited NAV for August 2022
15th Sep 20227:00 amEQSUnaudited NAV for August 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20227:01 amEQSInterim Results for the Six Months Ended 30 June 2022
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:00 amEQSInterim Results for the Six Months Ended 30 June 2022
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jun 20224:45 pmEQSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.